Pediatric toxic epidermal necrolysis treated successfully with infliximab

Lana Chafranska; Ditte M. Saunte; Nille Behrendt; Ulrikka Nygaard; Ryan J. Christensen; Carsten Sand; Gregor B. Jemec

doi:10.1111/pde.13778

Pediatric toxic epidermal necrolysis treated successfully with infliximab

Lana Chafranska^*, Ditte M. Saunte, Nille Behrendt, Ulrikka Nygaard, Ryan J. Christensen, Carsten Sand, Gregor B. Jemec

^*Corresponding author for this work

Department of Clinical Medicine

8 Citations (Scopus)

Abstract

Successful management of toxic epidermal necrolysis (TEN) with tumor necrosis factor-α inhibitors has been described in adults. We present a case of a 7-year-old boy with infection-associated TEN, diagnosed by typical clinical and histopathological features, most likely caused by Mycoplasma pneumoniae. Treatment with a single dose of infliximab 5 mg/kg intravenously on day 5 after the onset of symptoms was followed by cessation of all blister formation over 3 days and complete resolution within a week. Sequelae were mild, consisting of postinflammatory hyperpigmentation and dry eyes.

Original language	English
Journal	Pediatric Dermatology
Volume	36
Issue number	3
Pages (from-to)	342-345
Number of pages	4
ISSN	0736-8046
DOIs	https://doi.org/10.1111/pde.13778
Publication status	Published - 2019

Keywords

infliximab
mycoplasma pneumoniae
Stevens-Johnson syndrome
toxic epidermal necrolysis
toxic epidermal necrolysis, alpha inhibitor

Access to Document

10.1111/pde.13778

Cite this

@article{9010ecc686764fde885e1fd1d5503a3c,

title = "Pediatric toxic epidermal necrolysis treated successfully with infliximab",

abstract = "Successful management of toxic epidermal necrolysis (TEN) with tumor necrosis factor-α inhibitors has been described in adults. We present a case of a 7-year-old boy with infection-associated TEN, diagnosed by typical clinical and histopathological features, most likely caused by Mycoplasma pneumoniae. Treatment with a single dose of infliximab 5 mg/kg intravenously on day 5 after the onset of symptoms was followed by cessation of all blister formation over 3 days and complete resolution within a week. Sequelae were mild, consisting of postinflammatory hyperpigmentation and dry eyes.",

keywords = "infliximab, mycoplasma pneumoniae, Stevens-Johnson syndrome, toxic epidermal necrolysis, toxic epidermal necrolysis, alpha inhibitor",

author = "Lana Chafranska and Saunte, {Ditte M.} and Nille Behrendt and Ulrikka Nygaard and Christensen, {Ryan J.} and Carsten Sand and Jemec, {Gregor B.}",

year = "2019",

doi = "10.1111/pde.13778",

language = "English",

volume = "36",

pages = "342--345",

journal = "Pediatric Dermatology",

issn = "0736-8046",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Pediatric toxic epidermal necrolysis treated successfully with infliximab

AU - Chafranska, Lana

AU - Saunte, Ditte M.

AU - Behrendt, Nille

AU - Nygaard, Ulrikka

AU - Christensen, Ryan J.

AU - Sand, Carsten

AU - Jemec, Gregor B.

PY - 2019

Y1 - 2019

N2 - Successful management of toxic epidermal necrolysis (TEN) with tumor necrosis factor-α inhibitors has been described in adults. We present a case of a 7-year-old boy with infection-associated TEN, diagnosed by typical clinical and histopathological features, most likely caused by Mycoplasma pneumoniae. Treatment with a single dose of infliximab 5 mg/kg intravenously on day 5 after the onset of symptoms was followed by cessation of all blister formation over 3 days and complete resolution within a week. Sequelae were mild, consisting of postinflammatory hyperpigmentation and dry eyes.

AB - Successful management of toxic epidermal necrolysis (TEN) with tumor necrosis factor-α inhibitors has been described in adults. We present a case of a 7-year-old boy with infection-associated TEN, diagnosed by typical clinical and histopathological features, most likely caused by Mycoplasma pneumoniae. Treatment with a single dose of infliximab 5 mg/kg intravenously on day 5 after the onset of symptoms was followed by cessation of all blister formation over 3 days and complete resolution within a week. Sequelae were mild, consisting of postinflammatory hyperpigmentation and dry eyes.

KW - infliximab

KW - mycoplasma pneumoniae

KW - Stevens-Johnson syndrome

KW - toxic epidermal necrolysis

KW - toxic epidermal necrolysis, alpha inhibitor

U2 - 10.1111/pde.13778

DO - 10.1111/pde.13778

M3 - Journal article

C2 - 30834560

AN - SCOPUS:85062497811

SN - 0736-8046

VL - 36

SP - 342

EP - 345

JO - Pediatric Dermatology

JF - Pediatric Dermatology

IS - 3

ER -

Pediatric toxic epidermal necrolysis treated successfully with infliximab

Abstract

Keywords

Access to Document

Fingerprint

Cite this